BCL9 and neoplasm: This reduction may be attributed to the interference of CA with β‐catenin/BCL9 interactions,[28] leading to a diminished infiltration of immunosuppressive T cells into the tumor and consequently enhancing the responsiveness of ABCA‐treated tumors to Anti‐PD1 therapy.